ATE241642T1 - Verbessertes verfahren zur rückfaltung der proteine - Google Patents
Verbessertes verfahren zur rückfaltung der proteineInfo
- Publication number
- ATE241642T1 ATE241642T1 AT94906891T AT94906891T ATE241642T1 AT E241642 T1 ATE241642 T1 AT E241642T1 AT 94906891 T AT94906891 T AT 94906891T AT 94906891 T AT94906891 T AT 94906891T AT E241642 T1 ATE241642 T1 AT E241642T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- factor
- recognition sites
- novel
- correctly folded
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 108010074860 Factor Xa Proteins 0.000 abstract 4
- 235000018102 proteins Nutrition 0.000 abstract 4
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 108010022999 Serine Proteases Proteins 0.000 abstract 1
- 102000012479 Serine Proteases Human genes 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 238000001212 derivatisation Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000003000 inclusion body Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 238000004153 renaturation Methods 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
- C12N2310/1241—Tetrahymena
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK13093A DK13093D0 (da) | 1993-02-04 | 1993-02-04 | Processing of proteins |
DK13993A DK13993D0 (da) | 1993-02-05 | 1993-02-05 | Processing of proteins |
PCT/GB1993/002492 WO1994013804A1 (en) | 1992-12-04 | 1993-12-03 | Multivalent and multispecific binding proteins, their manufacture and use |
PCT/DK1994/000054 WO1994018227A2 (en) | 1993-02-04 | 1994-02-04 | Improved method for the refolding of proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE241642T1 true ATE241642T1 (de) | 2003-06-15 |
Family
ID=26063372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94906891T ATE241642T1 (de) | 1993-02-04 | 1994-02-04 | Verbessertes verfahren zur rückfaltung der proteine |
Country Status (14)
Country | Link |
---|---|
US (2) | US5739281A (de) |
EP (1) | EP0686162B1 (de) |
JP (1) | JP3695467B2 (de) |
KR (1) | KR100310739B1 (de) |
AT (1) | ATE241642T1 (de) |
AU (1) | AU674568B2 (de) |
CA (1) | CA2155335C (de) |
DE (1) | DE69432744T2 (de) |
DK (1) | DK0686162T3 (de) |
ES (1) | ES2199959T3 (de) |
FI (1) | FI113272B (de) |
NO (1) | NO316274B1 (de) |
NZ (1) | NZ261571A (de) |
WO (1) | WO1994018227A2 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3695467B2 (ja) * | 1993-02-04 | 2005-09-14 | ボレアン ファーマ エー/エス | タンパクを再生するための改良された方法 |
AU6284896A (en) * | 1995-06-22 | 1997-01-22 | Eli Lilly And Company | Obesity protein intermediates and their preparation and use |
US7368111B2 (en) | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
AU703145B2 (en) * | 1995-11-07 | 1999-03-18 | Toshio Tanaka | Method for expression cloning of gene encoding ligand-bound protein |
US6277618B1 (en) * | 1996-06-06 | 2001-08-21 | Roche Diagnostics Gmbh | Recombinant blood-coagulation proteases |
DE69827507T2 (de) | 1997-06-11 | 2006-03-09 | Borean Pharma A/S | Trimerisierendes modul |
US20030207402A1 (en) * | 1997-08-22 | 2003-11-06 | Erhard Kopetzki | Autocatalytically activatable zymogenic precursors of proteases and their use |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
DK1276855T3 (da) * | 2000-04-17 | 2012-11-26 | Dyax Corp | Fremgangsmåde til konstruktion af visningsbiblioteker over genetiske pakker for medlemmer af en diversificeret peptidfamilie |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
US20030212248A1 (en) * | 2000-07-12 | 2003-11-13 | Furman Thomas Charles | Process to increase protein stability |
WO2002024929A2 (en) * | 2000-09-22 | 2002-03-28 | Ramot At Tel Aviv University Ltd | A SOLUBLE BETA 2 MICROGLOBULIN (β2M)/HFE MONOCHAIN FOR BIOTECHNOLOGICAL AND THERAPEUTIC APPLICATIONS |
CA2428114C (en) | 2000-11-10 | 2013-07-23 | Proteopharma Aps | Apolipoprotein analogues |
US20040132094A1 (en) | 2000-12-13 | 2004-07-08 | Michael Etzerodt | Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains |
WO2002048189A2 (en) | 2000-12-13 | 2002-06-20 | Borean Pharma A/S | Combinatorial libraries of proteins having the scaffold structure of c-type lectin-like domains |
DE60144063D1 (de) | 2000-12-18 | 2011-03-31 | Dyax Corp | Gerichtete bibliotheken die genetisch verpackt sind |
US20060252917A1 (en) * | 2001-02-08 | 2006-11-09 | University Of Utah | Methods for refolding conformationally constrained peptides |
DE10105912A1 (de) * | 2001-02-09 | 2002-08-14 | Roche Diagnostics Gmbh | Rekombinante Proteinase K |
AU2003249014B2 (en) * | 2002-07-09 | 2009-07-02 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP1382614A1 (de) * | 2002-07-15 | 2004-01-21 | Bayer HealthCare AG | Verfahren zur Reinigung von Interleukin-4 und seinen Muteinen |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
US20040072262A1 (en) * | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
CN101899106A (zh) | 2002-10-29 | 2010-12-01 | 阿纳福公司 | 三聚细胞因子的三聚结合蛋白 |
AU2003300785A1 (en) * | 2002-11-12 | 2004-06-03 | Incyte Corporation | Carbohydrate-associated proteins |
EP2308901B1 (de) | 2003-04-23 | 2017-11-08 | F. Hoffmann-La Roche AG | Spaltung von Fusionsproteinen durch Verwendung von Granzyme B Protease |
US20100028995A1 (en) * | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
US7482148B2 (en) * | 2004-03-30 | 2009-01-27 | Sudershan Biotech Ltd. | Recombinant calf-chymosin and a process for producing the same |
WO2006060083A1 (en) * | 2004-10-22 | 2006-06-08 | Amgen Inc. | Methods for refolding polypeptides |
US8940871B2 (en) * | 2006-03-20 | 2015-01-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting |
EP1845103B1 (de) * | 2006-04-10 | 2015-02-25 | Boehringer Ingelheim RCV GmbH & Co KG | Verfahren zur Proteinfaltung |
US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
EP3753947A1 (de) | 2007-09-14 | 2020-12-23 | Adimab, LLC | Synthetische antikörperbibliotheken mit rationalem design und verwendungen davon |
US8324151B2 (en) * | 2007-11-20 | 2012-12-04 | The Feinstein Institute For Medical Research | Treatment of sepsis and septic shock using ghrelin and growth hormone |
WO2009114815A1 (en) | 2008-03-13 | 2009-09-17 | Dyax Corp | Libraries of genetic packages comprising novel hc cdr3 designs |
CA2968164C (en) | 2008-04-24 | 2019-08-20 | Dyax Corp. | Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs |
ES2550384T3 (es) * | 2008-12-18 | 2015-11-06 | Dana-Farber Cancer Institute, Inc. | NKG2D-Fc para la inmunoterapia |
JP2013504602A (ja) * | 2009-09-14 | 2013-02-07 | ダイアックス コーポレーション | 新しく設計したhccdr3を含む遺伝子パッケージライブラリー |
EP2787083B1 (de) * | 2009-11-09 | 2017-06-14 | The Regents of the University of Colorado, a body corporate | Effiziente herstellung von peptiden |
CN103282560B (zh) | 2010-07-16 | 2016-08-03 | 阿迪马布有限责任公司 | 抗体文库 |
EP2420253A1 (de) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Manipulation multifunktioneller und multivalenter Moleküle mit Kollagen-XV-Trimerisationsdomäne |
EP2646465B1 (de) | 2010-10-15 | 2018-09-12 | Leadartis, S.L. | Erzeugung multifunktionaler und multivalenter polypeptidkomplexe mit kollagen-xviii-trimerisationsdomäne |
EP2441776A1 (de) | 2010-10-15 | 2012-04-18 | Leadartis, S.L. | Erzeugung multifunktionaler und multivalenter Polypeptidkomplexe mit Kollagen-XVIII-Trimerisationsdomäne |
CN106661119A (zh) | 2014-07-01 | 2017-05-10 | 辉瑞公司 | 双特异性异二聚化双抗体及其用途 |
AU2016353231B2 (en) | 2015-11-13 | 2020-08-13 | Dana-Farber Cancer Institute, Inc. | An NKG2D-Ig fusion protein for cancer immunotherapy |
EP3802601A1 (de) | 2018-06-06 | 2021-04-14 | Leadartis, S.L. | Trimere polypeptidkomplexe und verwendungen davon |
US20240092942A1 (en) | 2021-03-05 | 2024-03-21 | Leadartis, S.L. | Trimeric polypeptides and uses thereof in the treatment of cancer |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1200773A (en) * | 1980-02-29 | 1986-02-18 | William J. Rutter | Expression linkers |
US4444878A (en) * | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
ATE107356T1 (de) * | 1983-03-25 | 1994-07-15 | Celltech Ltd | Verfahren zur herstellung eines proteins. |
GB8412517D0 (en) * | 1984-05-16 | 1984-06-20 | Nagai K | Recombinant fusion proteins |
GB8508340D0 (en) * | 1985-03-29 | 1985-05-09 | Creighton T E | Production of protein |
US4656255A (en) * | 1985-09-09 | 1987-04-07 | International Minerals & Chemical Corp. | Protein recovery |
CA1340522C (en) * | 1987-03-10 | 1999-05-04 | Heinz Dobeli | Fusion proteins containing neighbouring histidines for improved purification |
US5074977A (en) * | 1987-05-05 | 1991-12-24 | The Washington Technology Center | Digital biosensors and method of using same |
US4999422A (en) * | 1988-04-15 | 1991-03-12 | Biogen, N.V. | Continuous method of refolding proteins |
US5231168A (en) * | 1988-09-16 | 1993-07-27 | Statens Seruminstitut | Malaria antigen |
DE3835350A1 (de) * | 1988-10-17 | 1990-04-19 | Boehringer Mannheim Gmbh | Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern |
DK0432419T3 (da) * | 1989-12-05 | 1994-11-14 | American Cyanamid Co | Fremgangsmåde til solubilisering og naturering af somatotropiner under anvendelse af lav urinstofkoncentration |
US5324436A (en) * | 1991-12-13 | 1994-06-28 | The Administrators Of The Tulane Educational Fund | Use of hydrate formation to control membrane mimetic systems |
JP3695467B2 (ja) * | 1993-02-04 | 2005-09-14 | ボレアン ファーマ エー/エス | タンパクを再生するための改良された方法 |
-
1994
- 1994-02-04 JP JP51754494A patent/JP3695467B2/ja not_active Expired - Fee Related
- 1994-02-04 CA CA002155335A patent/CA2155335C/en not_active Expired - Fee Related
- 1994-02-04 AT AT94906891T patent/ATE241642T1/de active
- 1994-02-04 KR KR1019950703244A patent/KR100310739B1/ko not_active IP Right Cessation
- 1994-02-04 DE DE69432744T patent/DE69432744T2/de not_active Expired - Lifetime
- 1994-02-04 WO PCT/DK1994/000054 patent/WO1994018227A2/en active IP Right Grant
- 1994-02-04 AU AU60380/94A patent/AU674568B2/en not_active Ceased
- 1994-02-04 DK DK94906891T patent/DK0686162T3/da active
- 1994-02-04 NZ NZ261571A patent/NZ261571A/en not_active IP Right Cessation
- 1994-02-04 ES ES94906891T patent/ES2199959T3/es not_active Expired - Lifetime
- 1994-02-04 EP EP94906891A patent/EP0686162B1/de not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/469,486 patent/US5739281A/en not_active Expired - Lifetime
- 1995-07-28 NO NO19952989A patent/NO316274B1/no not_active IP Right Cessation
- 1995-08-03 FI FI953705A patent/FI113272B/fi not_active IP Right Cessation
- 1995-09-18 US US08/469,658 patent/US5917018A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1994018227A3 (en) | 1994-10-13 |
FI113272B (fi) | 2004-03-31 |
NO952989D0 (no) | 1995-07-28 |
DK0686162T3 (da) | 2003-09-22 |
FI953705A (fi) | 1995-08-03 |
US5917018A (en) | 1999-06-29 |
KR960701083A (ko) | 1996-02-24 |
DE69432744T2 (de) | 2004-03-25 |
WO1994018227A2 (en) | 1994-08-18 |
DE69432744D1 (de) | 2003-07-03 |
KR100310739B1 (ko) | 2002-05-30 |
NO952989L (no) | 1995-10-03 |
US5739281A (en) | 1998-04-14 |
EP0686162B1 (de) | 2003-05-28 |
FI953705A0 (fi) | 1995-08-03 |
AU6038094A (en) | 1994-08-29 |
NO316274B1 (no) | 2004-01-05 |
NZ261571A (en) | 1997-03-24 |
CA2155335A1 (en) | 1994-08-18 |
EP0686162A1 (de) | 1995-12-13 |
CA2155335C (en) | 2001-06-05 |
JP3695467B2 (ja) | 2005-09-14 |
AU674568B2 (en) | 1997-01-02 |
JPH08506243A (ja) | 1996-07-09 |
ES2199959T3 (es) | 2004-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE241642T1 (de) | Verbessertes verfahren zur rückfaltung der proteine | |
ATE110414T1 (de) | System zur bearbeitung von hefe, welches eine zur bearbeitungsstelle benachbarte negativ geladene aminosäure beeinhaltet. | |
CY1111322T1 (el) | Προϊοντα υδρολυσης πρωτεϊνων εμπλουτισμενα σε πεπτιδια που εχουν ενα καρβοξυ-τερματικο υπολειμμα προλινης | |
FI961886A (fi) | Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit | |
ATE76900T1 (de) | Modifizierter faktor vii/viia. | |
ATE265538T1 (de) | Verfahren zur sekretion thrombopoitin polypeptide | |
DE60230274D1 (de) | Verfahren zur herstellung von l-aminosäuren durch enterobacteriaceae-stämmen mit verstärkter expression des pts-g | |
HUP0400588A2 (hu) | A von Willebrand faktort (vWF) hasító proteáz polipeptid, a polipeptidet kódoló nukleinsav, és a polipeptid használata | |
Baramova et al. | Identification of the cleavage sites by a hemorrhagic metalloproteinase in type IV collagen | |
DK0642307T3 (da) | Fremgangsmåde til fremstilling af et valleproteinhydrolysat og et valleproteinhydrolysat | |
DK0901526T3 (da) | Cortistatin: neuropeptider, sammensætninger og metoder | |
ES2134834T3 (es) | Procedimiento para escindir proenzimas. | |
MX9306021A (es) | Nueva dipeptidil amino peptidasa aislada del moho del limo celular dictyostelium discoideum y metodopara su aislamiento. | |
DE60040771D1 (de) | Verfahren zur kontrolle der spaltung mit ompt protease | |
DE3873273D1 (de) | Verfahren zur selektiven spaltung von fusionsproteinen. | |
ATE144551T1 (de) | Methode zur produktion von glukagon | |
ATE319837T1 (de) | Verfahren zur herstellung von rekombinantem trypsin | |
DE50001961D1 (de) | Verfahren zur herstellung von eiweisshydrolysaten | |
ATE224403T1 (de) | Verwendung von kaseinfragmenten als wachstumerförderer | |
NO20030684D0 (no) | Fremgangsmåter for å forbedre egenskaper av kjöttkvaliteten i produkter, samt et proteinhydrolysat fremstilt av et fiskemateriale | |
EP0945512A3 (de) | Serinproteasen | |
WO2002081708A1 (fr) | Procede de production de prothease thiol d3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0686162 Country of ref document: EP |
|
EEIH | Change in the person of patent owner | ||
EEIH | Change in the person of patent owner |